| HOME >> MEDICINE >> TECHNOLOGY |
EVC GroupDavid Kaysen, President and CEO, or
Doug Sherk/Jenifer Kirtland (Investors)Medi Jiwani, Vice President, CFO, and
415.896.6820Treasurer
Chris Gale (Media)952.426.6140
646.201.5431UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)Three Months EndedSeptember 30,Six Months EndedSeptember 30,2010200920102009Net sales
$3,244,823$2,986,475$6,280,322$5,812,404Cost of goods sold
594,469535,0741,105,1651,087,044Gross profit
2,650,3542,451,4015,175,1574,725,360Operating expensesGeneral and administrative
897,368713,0401,747,6851,561,591Research and development
472,008435,898872,637963,713Selling and marketing
2,017,4201,968,0544,005,9464,025,342Amortization
210,682211,503421,450423,3163,597,4783,328,4957,047,7186,973,962Operating loss
(947,124)(877,094)(1,872,561)(2,248,602)Other income (expense)Interest income
17,99924,23031,62755,629Interest expense
(1,938)(1,788)(3,885)(9,694)Foreign currency exchange gain (loss)
10,574(7,365)12,364(14,697)Other, net
-2,000(192)(183)26,63517,07739,91431,055Loss before income taxes
(920,489)(860,017)(1,832,647)(2,217,547)Income tax expense
2,18314,64219,33322,887Net loss
$(922,672)$(874,659)$(1,851,980)$(2,240,434)Basic and diluted loss per common share
$(0.05)$(0.06)$(0.11)$(0.15)Weighted average common shares outstanding:Basic and diluted
19,088,24914,946,54017,207,95714,942,179UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)September 30, 2010March 31, 2010AssetsCurrent assets:Cash and cash equivalents & short-term investments
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2010 PR Newswire. All rights reserved |